Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (181-190 of 260) with videos related to

Pageof 26
Sort By:
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib TrialAmita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeCharlie Gourley, Caroline O Michie, Patricia Roxburgh, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Nature Medicine|October 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trialTimothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in <i>BRCA1</i> and <i>BRCA2</i> by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
Plos One|November 13, 2012
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancersGeraldine Perkins, Timothy A Yap, Lorna Pope, et al.
Pageof 26

Showing results (181-190 of 260) with videos related to

Sort By:
Pageof 26
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib TrialAmita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeCharlie Gourley, Caroline O Michie, Patricia Roxburgh, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Nature Medicine|October 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trialTimothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in <i>BRCA1</i> and <i>BRCA2</i> by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
Plos One|November 13, 2012
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancersGeraldine Perkins, Timothy A Yap, Lorna Pope, et al.
Pageof 26